Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Why you should donate blood, briefly explained
- 3 گھنٹے قبل
Follistatin-344: a multifaceted regulatory peptide
- 13 گھنٹے قبل
Security forces neutralise seven Khwarij in North Waziristan: ISPR
- 12 گھنٹے قبل
Alhamra Sufi Festival concludes with remarkable splendor
- 12 گھنٹے قبل
How to break free of “money dysmorphia” — and 3 other tips on generosity
- 3 گھنٹے قبل
UCL talking points: Pep's tinkering costs City, Arsenal look unstoppable
- 4 گھنٹے قبل
Air Chief hails PAF’s performance in ‘Maarka-e-Haq’
- 12 گھنٹے قبل
Why is the US on the verge of war with Venezuela?
- 3 گھنٹے قبل
The end of malaria
- 3 گھنٹے قبل
Men's boxing pound-for-pound rankings: Haney in, Canelo out, Benavidez moves up
- 4 گھنٹے قبل
What happens when women lead? A new future for Bangladesh
- 3 گھنٹے قبل
How Tyrese Maxey went from the hardwood to the 2025 National Dog Show
- 4 گھنٹے قبل
